ArticleBiomaterials2011
Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles.
Article in Biomaterials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 139 citations in OpenAlex.
- Niosomal l-carnitine and quercetin improve sperm quality and testicular function in atrazine-induced reproductive toxicity in rats.Scientific reports · 2026Article
- Targeting of Bacteria Using Amylase-Degradable, Copper-Loaded Starch Nanoparticles.Antibiotics (Basel, Switzerland) · 2026Article
- Combating Antimicrobial Resistance: Innovative Strategies Using Peptides, Nanotechnology, Phages,Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Next Frontier: Unveiling Novel Approaches for Combating Multidrug-Resistant Bacteria.Pharmaceutical research · 2025Review
- Revolutionizing Nanovaccines: A New Era of Immunization.Vaccines · 2025Review
- Salmon-IgM Functionalized-PLGA Nanosystem for Florfenicol Delivery as an Antimicrobial Strategy againstNanomaterials (Basel, Switzerland) · 2024Article
- PLGA Particles in Immunotherapy.Pharmaceutics · 2023Review
- Nanomedicine: New Frontiers in Fighting Microbial Infections.Nanomaterials (Basel, Switzerland) · 2023Review
- 3D-printed dual drug delivery nanoparticle- loaded hydrogels to combat antibiotic-resistant bacteria.International journal of bioprinting · 2023Article
- Bacterial infection microenvironment-responsive porous microspheres by microfluidics for promoting anti-infective therapy.Smart medicine · 2022Article
- Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.Advanced therapeutics · 2022Article
- PLGA-Based Composites for Various Biomedical Applications.International journal of molecular sciences · 2022Review
- Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 againstPharmaceutics · 2022Article
- On-demand pH-sensitive surface charge-switchable polymeric micelles for targeting Pseudomonas aeruginosa biofilms development.Journal of nanobiotechnology · 2021Article
- Nanotechnology approaches for global infectious diseases.Nature nanotechnology · 2021Review
- Degradable polymeric vehicles for postoperative pain management.Nature communications · 2021Review
- Encapsulation of Andrographolide in poly(lactide-co-glycolide) Nanoparticles: Formulation Optimization andFrontiers in bioengineering and biotechnology · 2021Article
- Nanoantibiotics: Functions and Properties at the Nanoscale to Combat Antibiotic Resistance.Frontiers in chemistry · 2021Review
- Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections.Molecules (Basel, Switzerland) · 2020Review
- Rifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections.Antibiotics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Chlamydia trachomatis and Chlamydia pneumoniae are intracellular bacterial pathogens that have been shown to cause, or are strongly associated with, diverse chronic diseases. Persistent infections by both organisms are refractory to antibiotic therapy. The lack of therapeutic efficacy results from the attenuated metabolic rate of persistently infecting chlamydiae in combination with the modest intracellular drug concentrations achievable by normal delivery of antibiotics to the inclusions within which chlamydiae reside in the host cell cytoplasm. In this research, we evaluated whether nanoparticles formulated using the biodegradable poly(d-L-lactide-co-glycolide) (PLGA) polymer can enhance the delivery of antibiotics to the chlamydial inclusion complexes. We initially studied the trafficking of PLGA nanoparticles in Chlamydia-infected cells. We then evaluated nanoparticles for the delivery of antibiotics to the inclusions. Intracellular trafficking studies show that PLGA nanoparticles efficiently concentrate in inclusions in both acutely and persistently infected cells. Further, encapsulation of rifampin and azithromycin antibiotics in PLGA nanoparticles enhanced the effectiveness of the antibiotics in reducing microbial burden. Combination of rifampin and azithromycin was more effective than the individual drugs. Overall, our studies show that PLGA nanoparticles can be effective carriers for targeted delivery of antibiotics to intracellular chlamydial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.